Download presentation
Presentation is loading. Please wait.
Published bySamantha Payne Modified over 8 years ago
1
September 24, 2010
2
20% diagnosed in childhood Mostly in adolescence F:M ratio Prior to puberty - 3:1 After puberty - 9:1 Native Americans > African Americans > Hispanics > Chinese > Filipinos More severe disease in AA and Hispanics Multigenic
3
Most common symptoms in teenagers Fever Rash Mucositis Arthritis Constitutional ▪ Weight loss ▪ Malaise
4
Butterfly rash Malar erythema Photosensitive Sparing of nasolabial folds Discoid lesions Scalp or extremities Photosensitive Maculopapular lesions Occur anywhere
5
Alopecia Begins frontal Spreads diffusely Rarely permanent Vasculitic Palmar erythema Mucosal lesions Ulcers Sometimes painless
6
2 nd leading cause of morbidity and mortality Psychiatric Psychosis Seizures HA Lupus cerebritis ▪ Also difficulty with concentration, memory, depression or decline in school performance Less commonly Chorea, neuropathies, transverse myelitis
7
Any layer of the heart affected Pericardium Most common Myocarditis CHF, arrhythmia Libman-Sacks endocarditis At risk for SBE
8
Raynaud phenomenon Very common in adolescents Cold, emotional stress, caffeine, cigarette smoke At risk for infarction Premature atherosclerosis
9
Pleuropulmonary disease Pleuritic chest pain ▪ Effusion 60% of adolescent patients will have abnormal PFTs Other Pneumonitis Pulmonary Hemorrhage Pulmonary HTN
10
Abdominal pain is common Pancreatitis Mesenteric vasculitis Peritonitis Hepatitis Question #2
11
#1 cause of morbidity 75% of children within first 2 years Signs Microscopic hematuria and proteinuria HTN Decreased GFR Elevated BUN or Cr
12
Renal Biopsy
13
Arthralgia Arthritis Nonerosive, nondeforming Small and large joints Myalgia Proximal muscle weakness Myositis Possible MCTD
14
Cytopenia Any cell line Anemia 50% ▪ Normocytic normochromic ▪ Anemia of chronic disease or autoimmune hemolytic ITP
16
ANA Best screening test Positive in almost all that have active disease Not specific More specific if ≥ 1:1,280 Other diseases ▪ JIA, Dermatomyositis, scleroderma, thyroid disease
18
Complement (C3, C4) Reduced levels May indicate need for aggressive therapy
19
Antiphospholipid antibodies CBC Electrolytes BUN and Cr Hepatic Enzymes Acute-phase reactants UA
20
Consult with Rhematology Treatment depends on clinical manifestations Emerging morbidity is associated with treatment Close monitoring
22
Improving Juvenile-onset 92% - 5 year survival rate 85% - 10 year survival rate Major causes of death Renal disease Infection CNS disease
Similar presentations
© 2024 SlidePlayer.com. Inc.
All rights reserved.